- Clinical Trials
Our oncology platform technologies have been designed and optimized to administer cancer-fighting genes to large patient populations who currently have limited treatment options. We are developing our lead product candidate to be administered in combination with approved therapies, such as targeted therapies and immunotherapies, for NSCLC. We have conducted a Phase I/II targeted therapy clinical trial evaluating REQORSA™ immunogene therapy in combination with EGFR inhibitor Tarceva. We have conducted preclinical research evaluating REQORSA in combination with EGFR inhibitor Tagrisso, as well as REQORSA™ in combination with checkpoint inhibitor Keytruda. Genprex continues to conduct preclinical research to explore how REQORSA™ may be administered with targeted therapies and immunotherapies in other solid tumors. Investigators at the University of Pittsburgh are also continuing to conduct preclinical research on our diabetes gene therapy candidate. Our current research and development pipeline is shown below.
Tagrisso® is a registered trademark of AstraZeneca.
Keytruda® is a registered trademark of Merck.